Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    Special Populations
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    March 10, 2023
    How I Practice Mindfulness as an Oncology Nurse
    Nurse well-being
    How I Practice Mindfulness as an Oncology Nurse
    March 03, 2023
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Biotherapy

    Help Patients Understand Biomarker Test Results and Clinical Trials Options
    Genetics & genomics

    Help Patients Understand Biomarker Test Results and Clinical Trials Options

    Many of today’s new drug approvals and standard-of-care treatments have a companion diagnostic test that identifies biomarkers in a patient’s tumor tissue or blood to determine whether they are an appropriate candidate for the therapy. When those results show that they’re not a good match for the U.S. Food and Drug Administration (FDA)-approved treatment, the findings may identify a biomarker-directed clinical trial as an alternative option. Here’s how oncology nurses can help patients understand which clinical trials listed on their test results might be an option for them.

    December 16, 2021
    ONS Congress

    Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology

    Immune checkpoint inhibitors (ICPIs) enhance treatment response while minimizing toxicities for patients with cancer. However, education is key to managing the therapies’ unique adverse events (AEs). During a session for the ONS 46th Annual Congress™, Marianne Davies, DNP, ACNP, FAAN, of the Yale Comprehensive Cancer Center, Smilow Cancer Hospital at Yale New Haven Hospital, and the Yale University School of Nursing, and Laura S. Wood, RN, MSN, OCN®, of Cleveland Clinic Cancer Center, provided oncology nurses with a foundation for evaluating and grading AEs in immuno-oncology.

    April 22, 2021
    Health Care at Iowa Caucus; FDA Biologic Market; Flavored E-Cigarette Pod Ban
    Health Policy

    Health Care at Iowa Caucus; FDA Biologic Market; Flavored E-Cigarette Pod Ban

    The Iowa Democratic Caucus did not go as smoothly as the political prognosticators expected. Most news outlets are only reporting the level of dysfunction with a voting app that delayed the final numbers significantly, but beneath that is one truth that still rings true: Americans want solutions to their healthcare problems. Health care remained the number one policy issue for 41% of caucus attendees, an astoundingly high rate that beat every other issue handedly.

    February 10, 2020
    An Oncology Nursing Overview of Biosimilars
    Clinical practice

    An Oncology Nursing Overview of Biosimilars

    Since the first biosimilar agent was approved by the U.S. Food and Drug Administration (FDA) in 2015, patients and providers have had concerns about the implications for their care and practice, respectively. Because 6 of the 12 biosimilar drugs currently approved in the United States have indications for oncology practice, oncology nurses have a responsibility to understand the drugs’ safety and efficacy for the patients in their care.

    November 13, 2018
    Biosimilar to Pegfilgrastim
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Biosimilar to Pegfilgrastim to Decrease Cancer Treatment Infection Risk

    On June 4, 2018, the U.S. Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila) as a biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

    June 05, 2018
    Health Policy Advances Cancer Treatment Options in the Era of Biosimilars
    Health Policy

    Health Policy Advances Cancer Treatment Options in the Era of Biosimilars

    Options and cost are a double-edged sword as biomedical research marches forward and the list of approved drugs expands. More targeted drugs for specific diseases means that more patients have treatment plans that can directly fight their specific disease, possibly resulting in cures.

    June 04, 2018
    Biosimilars Offer New Options for Treatment and New Concepts for Patient Education
    Biotherapy

    Biosimilars Offer New Options for Treatment and New Concepts for Patient Education

    The list of pharmacologic agents used in cancer care is expanding: chemotherapy, biotherapy, immunotherapy, targeted therapy, hormonal therapy, and now biosimilars. Part of being a nurse leader is recognizing trends in cancer care, changes on the horizon, and their impact on your patients and cancer treatment options. Biosimilars represent one such trend that affects providers’ approach to care and the education that oncology nurses must provide to patients and caregivers.

    April 24, 2018
    ASCO Annual Meeting

    Study Assesses Response to Pembrolizumab Based on Biomarkers in Patients With Soft Tissue or Bone Sarcomas

    The multicenter, phase II SAR028 clinical trial was the first to study pembrolizumab monotherapy in patients with soft tissue sarcoma or bone sarcoma to assess the clinical efficacy signals in multiple histologies. The researchers presented extended follow-up data at the ASCO Annual Meeting.

    June 02, 2017
    Chemotherapy Competence
    Clinical practice

    What Is Chemotherapy Competence Versus Chemotherapy Certification?

    The ONS clinical inbox frequently receives questions about whether nurses need to be “chemotherapy certified” to give specific chemotherapy and/or biotherapy agents.

    January 28, 2017
    Test tubes filled with a clear liquid
    Biotherapy

    Biosimilar Treatments Have Practice Implications

    As biosimilars continue to gain popularity in cancer care, healthcare workers should be prepared to see them in their practice. Here’s what you need to know about this newer drug product.
    April 05, 2016
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲